What to Make of the Fed’s Latest Shocker w/ Danielle DiMartino Booth


It was another week filled with surprises from the U.S. Federal Reserve… On the heels of the latest FOMC meeting, Janet Yellen shared plans to hike interest rates twice this year, instead of the scheduled four. To help explain what this will mean for investors, Marc talks with Danielle DiMartino Booth, a former analyst with the Dallas Fed and founder of Money Strong, LLC.

Later, Marc checks in on the biotech sector – and discusses whether Canadian drug company Valeant Pharmaceuticals (NYSE: VRX) is a great contrarian buy… or the next Enron.

View the transcript.